Champions Oncology Inc (NASDAQ:CSBR) reached a new 52-week high during mid-day trading on Friday after the company announced better than expected quarterly earnings. The stock traded as high as $11.00 and last traded at $9.84, with a volume of 34973 shares traded. The stock had previously closed at $10.63.

The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. Champions Oncology had a negative return on equity of 531.69% and a negative net margin of 7.44%. The firm had revenue of $6.23 million for the quarter, compared to analyst estimates of $5.85 million.

Several brokerages recently issued reports on CSBR. Janney Montgomery Scott began coverage on Champions Oncology in a research note on Monday, July 9th. They set a “buy” rating on the stock. Craig Hallum began coverage on Champions Oncology in a research note on Tuesday, July 17th. They set a “buy” rating and a $12.00 price target on the stock. Finally, ValuEngine upgraded Champions Oncology from a “hold” rating to a “buy” rating in a research note on Tuesday, June 5th.

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Champions Oncology in the 2nd quarter valued at approximately $104,000. Renaissance Technologies LLC grew its stake in shares of Champions Oncology by 63.3% in the 2nd quarter. Renaissance Technologies LLC now owns 100,600 shares of the biotechnology company’s stock valued at $638,000 after purchasing an additional 39,000 shares during the period. Essex Investment Management Co. LLC bought a new stake in shares of Champions Oncology in the 2nd quarter valued at approximately $646,000. Perkins Capital Management Inc. bought a new stake in shares of Champions Oncology in the 2nd quarter valued at approximately $653,000. Finally, Tocqueville Asset Management L.P. bought a new stake in shares of Champions Oncology in the 2nd quarter valued at approximately $729,000. Institutional investors own 38.94% of the company’s stock.

The company has a market cap of $91.64 million, a price-to-earnings ratio of -75.57 and a beta of 0.12.

About Champions Oncology (NASDAQ:CSBR)

Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.

Featured Story: Understanding Average Daily Trade Volume

Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.